Haemonetics (NYSE: HAE) recently received a number of ratings updates from brokerages and research firms:
- 11/7/2026 – Haemonetics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
- 11/6/2026 – Haemonetics had its price target raised by Citigroup from $123.00 to $149.00. They now have a “buy” rating on the stock.
- 11/6/2026 – Haemonetics had its price target raised by Barrington Research from $140.00 to $145.00. They now have an “outperform” rating on the stock.
- 11/5/2026 – Haemonetics was given a new $165.00 price target by Mizuho.
- 11/5/2026 – Haemonetics had its price target raised by BTIG Research from $130.00 to $142.00. They now have a “buy” rating on the stock.
- 11/4/2026 – Haemonetics had its “hold (c)” rating reaffirmed by Weiss Ratings.
- 10/9/2026 – Haemonetics had its price target raised by Mizuho from $95.00 to $140.00. They now have an “outperform” rating on the stock.
- 10/9/2026 – Haemonetics had its price target raised by Barrington Research from $118.00 to $140.00. They now have an “outperform” rating on the stock.
- 10/8/2026 – Haemonetics had its price target raised by BTIG Research from $110.00 to $130.00. They now have a “buy” rating on the stock.
Haemonetics Stock Up 0.0%
HAE stock traded up $0.01 during trading on Tuesday, reaching $118.22. 68,021 shares of the company traded hands, compared to its average volume of 809,226. Haemonetics Corporation has a 12 month low of $51.00 and a 12 month high of $132.00. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08. The company has a market capitalization of $5.38 billion, a price-to-earnings ratio of 53.02, a price-to-earnings-growth ratio of 2.55 and a beta of 0.63. The business has a 50 day simple moving average of $111.77 and a 200 day simple moving average of $80.29.
Haemonetics (NYSE:HAE – Get Free Report) last released its earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The business had revenue of $357.76 million during the quarter, compared to analyst estimates of $345.15 million. During the same quarter in the prior year, the firm earned $1.27 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. On average, equities research analysts anticipate that Haemonetics Corporation will post 5.32 earnings per share for the current fiscal year.
Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals.
The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.
Founded in 1971, Haemonetics serves customers in multiple regions around the world.
Featured Stories
- Five stocks we like better than Haemonetics
- DraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
- Wall Street May Be Making a Big Mistake With monday.com Stock
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
